| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |